Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/ malignant solitary fibrous tumor (HPC/SFT): an updated analysis Park MS, Lazar AJ, Trent JC, Conrad CA, Ludwig JA, Wang W, Boonsirikamchai P, Choi H, Patel SR, Benjamin RS, Araujo DM The University of Texas - MD Anderson Cancer Center Houston, TX
Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/ malignant solitary fibrous tumor (HPC/SFT): an updated analysis. Park MS , Lazar AJ, Trent JC, Conrad CA, Ludwig JA, Wang W, Boonsirikamchai P, Choi H, Patel SR, Benjamin RS, Araujo DM - PowerPoint PPT Presentation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Combination therapy with temozolomide and bevacizumab in the treatment of
hemangiopericytoma/ malignant solitary fibrous tumor (HPC/SFT): an updated
analysis
Park MS, Lazar AJ, Trent JC, Conrad CA, Ludwig JA, Wang W, Boonsirikamchai P, Choi H, Patel SR, Benjamin RS, Araujo DM
The University of Texas - MD Anderson Cancer CenterHouston, TX
Background
Emerging consensus that HPC/SFT represent a
morphological continuum rather than two distinctentities1,2
The hemangiopericytoma/ solitary fibrous tumor (HPC/SFT) spectrum
Malignant potential of HPC/SFT is difficult to predict at the time of diagnosis
Limited data regarding the long-term outcome of HPC/SFT in the advanced setting3,4
3Spitz et al. Ann of Surg Oncol; 5(4):350-3554Espat et al. Cancer 2002;95:1746–51
Background Rationale for temozolomide & bevacizumab:
Activity in Glioblastomas5,6
Irinotecan and bevacizumab (RR 57-60%) Carboplatin and bevacizumab Temozolomide and bevacizumab
Our institution’s anecdotal experience in a single patient with meningeal HPC/SFT Previously heavily treated with multiple surgeries, XRT,
chemo- and biologic therapies with no prior response
5Vredenburgh et al. J Clin Oncol 2007;25:4722-27396Charles A. Conrad, personal communication
Methods Retrospective review of all HPC/SFT
patients treated with temozolomide and bevacizumab at MD Anderson Cancer Center IRB-approved protocol Study period: May 2005 – June 2007 All diagnoses confirmed by a sarcoma
pathologist All had follow-up scans available
Methods Radiologic response: Choi criteria7
7Choi et al. J Clin Oncol 2007;25:1753-1759
Statistical analysis for progression-free survial: Kaplan-Meier method
Results: Patient Characteristics 14 HPC/SFT patients treated with temozolomide &
bevacizumab at MD Anderson Cancer Center, 05/2005-06/2007
(HPC/SFT) are a rare spectrum of tumors with no known effective medical therapy in the advanced setting.
• In our retrospective series, combination therapy with temozolomide and bevacizumab has demonstrated clinical benefit in a majority of patients with a low rate of major toxicities.
• These findings advocate a role for a larger, prospective phase II study to further investigate the biological mechanism and efficacy of temozolomide and bevacizumab in HPC/SFT.